North America Antimicrobial Susceptibility Testing Market, By Product Type (Instruments, Consumables and Accessories and Services and Software), Methods (Mass Spectrometry Method, Dilution, Disk Diffusion, E-Test, Genotypic Methods and Others), Type (Antibacterial Testing, Antifungal Testing and Rapid-AST), Application (Clinical Diagnostics, Drug Discovery and Development, Epidemiology and Others), End-User (Hospitals, Pharmaceuticals and Biotechnology Companies, Diagnostic Laboratories, Contract Research Organizations, Research Centres and Academic Institutes and Others), Distribution Channel (Direct Sales, Retail Sales and Third Party Distributor) – Industry Trends and Forecast to 2030.
North America Antimicrobial Susceptibility Testing Market Analysis and Size
The North America antimicrobial susceptibility testing (AST) market continues to exhibit strong growth prospects, driven by the increasing prevalence of antibiotic-resistant infections in the region. Rising awareness about the importance of accurate susceptibility testing to guide effective antibiotic therapy and combat antimicrobial resistance has been a key catalyst for market expansion. Technological advancements in AST methods and the integration of automated systems have enhanced testing efficiency and accuracy.
Data Bridge Market Research analyses that the North America antimicrobial susceptibility testing market which was USD 1,814.88 million in 2022, is expected to reach USD 2,827.80 million by 2030, and is expected to undergo a CAGR of 5.70% during the forecast period. “Instruments” dominates the product type segment of the antimicrobial susceptibility testing market owing to the growing demand for instruments for antimicrobial testing. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
North America Antimicrobial Susceptibility Testing Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Instruments, Consumables and Accessories and Services and Software), Methods (Mass Spectrometry Method, Dilution, Disk Diffusion, E-Test, Genotypic Methods and Others), Type (Antibacterial Testing, Antifungal Testing and Rapid-AST), Application (Clinical Diagnostics, Drug Discovery and Development, Epidemiology and Others), End-User (Hospitals, Pharmaceuticals and Biotechnology Companies, Diagnostic Laboratories, Contract Research Organizations, Research Centres and Academic Institutes and Others), Distribution Channel (Direct Sales, Retail Sales and Third Party Distributor)
|
|
Countries Covered
|
U.S., Mexico, Canada
|
|
Market Players Covered
|
BD (U.S.), Synbiosis (U.K.), Zhuhai DL Biotech Co., Ltd (China), Mast Group Ltd. (U.K.), HiMedia Laboratories (India), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Creative Diagnostics (U.S.), Genefluidics, Inc. (U.S.), Rosco Diagnostica A/S (Denmark), ERBA Group (India), Liofilchem S.r.l. (Italy), Alifax S.r.l. (Germany), MERLIN Gesellschaft für mikrobiologische Diagnostika mbH (Germany), bioMérieux SA (France), Merck KGaA (Germany), Danaher (U.S.), Accelerate Diagnostics, Inc. (U.S.), NuMedii, Inc. (U.S.), and BacterioScan, Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Antimicrobial susceptibility testing (AST) is a laboratory procedure which is used to determine which antimicrobial impedes the growth of bacteria, fungi, and other microorganism causing a specific infection. Susceptibility testing is performed on microorganisms such as bacteria, fungi causing the infection after they have been recovered in a culture of the specimen.
Antibacterial drugs are playing the important role in the prevention of infectious diseases, however, the cases of drug misuse and overuse, led to the development of drug resistance. Delay in diagnosing the harmful microbes makes it difficult to control the spread of infectious diseases. This is putting pressure on the key players to manufacture the test kits which gives accurate and effective results to better treat the patients.
North America Antimicrobial Susceptibility Testing Market Dynamics
Drivers
- Rising Antibiotic Resistance
Increasing prevalence of antibiotic-resistant bacterial infections necessitates accurate antimicrobial susceptibility testing to guide effective antibiotic treatment. The growing concern about antimicrobial resistance is a significant driver for the market as healthcare providers seek better diagnostic tools to combat this global health threat.
- Technological Advancements in Antimicrobial Susceptibility Testing
Ongoing advancements in AST technologies, including automated systems, molecular diagnostics, and faster testing methods, enhance the efficiency and accuracy of susceptibility testing. These innovations drive market growth as healthcare facilities seek more precise and timely results.
- Demand for Infection Control
The COVID-19 pandemic has highlighted the importance of robust diagnostic capabilities and infection control measures. Healthcare facilities are investing in AST solutions to improve their diagnostic infrastructure, as infections become a major focus for public health.
- Growing Investment for Healthcare Facilities
Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.
Opportunities
- Rising Demand for Research and Development
Continued investment in research and development can lead to the creation of novel susceptibility testing techniques and the discovery of new biomarkers. Innovations in testing methods, such as genotypic and phenotypic assays, can open new avenues for personalized and precision medicine, creating opportunities for companies to develop and commercialize these cutting-edge technologies.
- Telemedicine and Remote Consultations
The rise of telemedicine and remote consultations offers an opportunity for companies to develop AST solutions that can integrate seamlessly with virtual healthcare platforms. These solutions can enable healthcare providers to discuss test results and treatment options remotely, improving patient access to care and convenience.
Restraints/ Challenges
- High Cost of Antimicrobial Susceptibility Testing
The initial investment and ongoing operational costs associated with advanced AST technologies can be prohibitive for some healthcare facilities, particularly smaller or resource-constrained settings. High costs can limit the adoption of these technologies and restrict market growth.
- Limited Healthcare Infrastructure in Underserved Areas
In some rural or underserved areas, healthcare facilities may lack the infrastructure and resources needed for advanced antimicrobial susceptibility testing. This limitation can hinder market penetration and equitable access to advanced diagnostic tools.
- Data Integration and Interoperability
The integration of AST data into electronic health records (EHRs) and healthcare information systems can be a challenge. Ensuring that the results of susceptibility testing are easily accessible to healthcare providers and that different AST systems can communicate with EHRs is crucial for streamlined patient care.
- Laboratory Capacity and Workforce
There is a shortage of skilled laboratory professionals capable of conducting AST and interpreting results accurately. The demand for susceptibility testing is increasing, and healthcare facilities may struggle to find and retain qualified staff to meet this demand. This challenge can lead to delays in test processing and result reporting.
This antimicrobial susceptibility testing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Antimicrobial Susceptibility Testing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In May 2022, Qualigen Therapeutics announced that NanoSynex Ltd, a company with whom Qualigen recently entered into definitive agreements to acquire a majority stake, featured at BioMed Israel. Innovative Technology by NanoSynex focuses to accelerate antimicrobial susceptibility test results times by six-fold
- In April 2022, COPAN Diagnostics demonstrated its range of fully automated solutions for identification and antimicrobial susceptibility testing (AST) in clinical microbiology at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2022). COPAN demonstrated the Food and Drug Administration-cleared Colibri, a fully automated specimen workup instrument designed to prepare MALDI-TOF ID targets and create bacterial suspensions for AST
North America Antimicrobial Susceptibility Testing Market Scope
The antimicrobial susceptibility testing market is segmented on the basis of product type, methods, type, application, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Instruments
- Consumables and accessories
- Services and software
Methods
- Mass Spectrometry Method
- Dilution
- Disk Diffusion
- E-test, Genotypic Methods
- Others
Type
- Antibacterial Testing
- Antifungal Testing
- Others
Application
- Clinical Diagnostics
- Drug Discovery and Development
- Epidemiology
- Others
End-User
- Hospitals
- Pharmaceuticals and Biotechnology Companies
- Diagnostic Laboratories
- Contract Research Organizations
- Research Centres and Academic Institutes
- Others
Distribution Channel
- Direct Sales
- Retail Sales
- Third Party Distributor
Antimicrobial Susceptibility Testing Market Regional Analysis/Insights
The antimicrobial susceptibility testing market is analysed and market size insights and trends are provided by product type, methods, type, application, end-user and distribution channel as referenced above.
The countries covered in the antimicrobial susceptibility testing market report are U.S., Canada and Mexico in North America.
U.S is dominating in North America market due rise in epidemic and pandemic events and presence of sophisticated healthcare infrastructure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and North America Antimicrobial Susceptibility Testing Market Share Analysis
The antimicrobial susceptibility testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company's focus related to antimicrobial susceptibility testing market.
Some of the major players operating in the antimicrobial susceptibility testing market are:
- BD (U.S.)
- Synbiosis (U.K.)
- Zhuhai DL Biotech Co., Ltd (China)
- Mast Group Ltd. (U.K.)
- HiMedia Laboratories (India)
- Thermo Fisher Scientific Inc.(U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- Creative Diagnostics(U.S.)
- Genefluidics, Inc. (U.S.)
- Rosco Diagnostica A/S (Denmark)
- ERBA Group (India)
- Liofilchem S.r.l. (Italy)
- Alifax S.r.l. (Germany)
- MERLIN Gesellschaft für mikrobiologische Diagnostika mbH (Germany)
- bioMérieux SA (France)
- Merck KGaA (Germany)
- Danaher (U.S.)
- Accelerate Diagnostics, Inc. (U.S.)
- NuMedii, Inc. (U.S.)
- BacterioScan, Inc. (U.S.)
SKU-